The purpose of this research is to understand how the body processes and responds to cefadroxil in patients who have a bloodstream infection. The study will examine how the medication moves through the body and how effective it is at fighting the infection. Participants will receive cefadroxil capsules for up to 6 months, with a maximum daily dose of 4 grams.

During the study, researchers will monitor how well the treatment works and watch for any side effects that may occur. The medication will only be given to patients whose infection has already shown improvement with initial treatment and who can take medications by mouth. This research will help determine the most appropriate dosing of cefadroxil for treating this type of infection.

The antibiotics being studied include several well-known medications such as Clarithromycin, Meropenem, Ceftriaxone, Cefotaxime, Piperacillin/Tazobactam, Vancomycin, Dicloxacillin, Flucloxacillin, Linezolid, Clindamycin, Levofloxacin, Moxifloxacin, Amikacin, Gentamicin, Benzylpenicillin, Cloxacillin, and Daptomycin. Some patients will receive a placebo, which is a substance with no active medication, to help compare the effects of the antibiotics. The purpose of the study is to find out if a shorter treatment period is just as effective as a longer one, which could help reduce side effects and healthcare costs.

Participants in the study will be randomly assigned to receive either seven or fourteen days of treatment. They will be monitored for 90 days after the start of the treatment to check for any signs of the infection returning or any other health issues. The study will also look at the overall health and survival of the participants during this period. This research is important for improving the treatment of Staphylococcus aureus bacteremia and ensuring patients receive the most effective care.

The purpose of the study is to determine if a shorter duration of antibiotic treatment, specifically four weeks, is as effective as the traditional six-week treatment for patients who have responded well to initial therapy. Participants in the study will receive one of the antibiotics mentioned above, or a placebo, to compare the outcomes. The study will monitor patients over a period to assess their response to the treatment and ensure there is no relapse of the infection.

Throughout the study, patients will be closely observed to ensure their safety and to evaluate the success of the therapy. The primary goal is to see if patients remain healthy and free from infection 180 days after starting the treatment. This research aims to provide insights into whether a shorter course of antibiotics can be just as effective, potentially leading to changes in how this infection is treated in the future.

The purpose of the study is to compare the outcomes of patients with this type of bacterial infection when treated with either bensylpenicillin or cloxacillin. Participants in the study will be randomly assigned to receive one of these two treatments. The study will monitor patients over a period to see how well they recover and if there are any complications or relapses within 90 days after finishing the antibiotic treatment.

The study will last for a maximum of seven days of treatment, and the main goal is to see if patients are alive and free of complications 90 days after treatment. Complications could include a return of the infection or the need to change or add antibiotics due to side effects or if the initial treatment does not work. This trial aims to provide valuable information on the effectiveness of these two antibiotics in treating Staphylococcus aureus bacteremia.

Participants in the study will receive cloxacillin through an intravenous route, meaning it will be administered directly into a vein. The study will monitor patients over a period of time to see how well the drug works and to check for any potential side effects. The researchers will pay special attention to how the drug levels relate to kidney function and whether patients reach the desired drug concentration in their blood. This will help in understanding if the standard dosing needs to be adjusted based on individual kidney function.

Throughout the study, various health markers will be observed, including any signs of kidney damage or changes in mental status, such as confusion or tremors. The study will also consider factors like age, weight, and other health conditions that might affect the treatment. By gathering this information, the study aims to improve the way cloxacillin is used to treat Staphylococcus aureus bacteremia, ensuring it is both safe and effective for patients with different levels of kidney function.

The purpose of the study is to examine how these treatments affect the overall survival of patients with this infection. Participants will be monitored for 90 days to assess their health outcomes, including survival rates and any side effects from the treatments. The study will also look at how long patients stay in the hospital and their recovery progress.

Throughout the study, participants will receive either one of the antibiotics or a placebo, and their health will be closely observed. The trial aims to provide valuable information on the effectiveness of these antibiotics in treating Staphylococcus aureus bacteremia and improving patient outcomes. This research could help guide future treatment options for this serious infection.